To help you efficiently navigate the complicated biological landscape of immune system caused by cancer immunotherapy, Creative Biolabs offers immunotoxicological studies to facilitate your preclinical testing and move your program efficiently forward to IND approval and further market approval. Accurate analysis of the immunotoxicological study results are critical to describe the therapeutic or adverse effects on the immune system.
Cancer immunotherapies are designed to modulate the immune system to treat cancer, improving our own natural ability to fight cancer. For unexpected consequences, we work closely with our clients with our expertise in immunotoxicology and immunology to isolate the adverse effects and push the program along the continuum. In Creative Biolabs, you can find a wide breadth of assays in immunotoxicology and immunology as biomarkers to monitor the potential safety risks and pharmaceutical efficacy via defining immune endpoints and changes in cell function.
■ T cell dependent antibody response | ■ Complement response | ■ Proliferation | ■ Natural killer (NK) cell activity |
■ T cell cytotoxicity | ■ ADCC/CDC | ■ Basophil | ■ Delayed-type hypersensitivity |
■ Cytokine/Chemokine • Profiling • Release |
■ Neutrophil/Macrophage • Oxidative burst activity • Phagocytosis • Migration |
■ Immuno-biomarker analysis • Cell activation • Cell apoptosis • Receptor occupancy and candidate molecule binding |
In Creative Biolabs, we assist our clients to realize immunotherapy efficiency with our wide range of assays in preclinical studies to move your candidate drug or therapy along the continuum. Please contact us for more detailed information.
For Research Use Only | Not For Clinical Use